日本受试者中两种质子泵抑制剂的抑酸作用与CYP2C19基因型的关系:一项随机双向交叉研究。
Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: a randomized two-way crossover study.
作者信息
Furuta K, Adachi K, Ohara S, Morita T, Tanimura T, Koshino K, Kinoshita Y
机构信息
Second Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo-shi, Shimane, Japan.
出版信息
J Int Med Res. 2010 Jul-Aug;38(4):1473-83. doi: 10.1177/147323001003800430.
This two-way crossover study investigated possible differences between the proton pump inhibitors, omeprazole and rabeprazole, in their effect on gastric acid secretion in Japanese subjects with differing cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) genotypes. A total of 23 Helicobacter pylori-negative healthy volunteers received omeprazole 20 mg/day and rabeprazole 10 mg/day. Each drug treatment was given for a continuous 7-day period allocated in random order, with an interval of at least 1 week between drug treatment periods to allow for wash-out. Intragastric pH was measured on days 1 and 7. Overall median intragastric pH levels at 7 and 8 h after the first administration were significantly higher with omeprazole. There was no significant difference in intragastric pH in homozygous extensive metabolizers, whereas intragastric pH was significantly higher with omeprazole in combined data from heterozygous extensive metabolizers and poor metabolizers at 6, 7 and 8 h after the first drug administration. There were no significant differences in intragastric pH between omeprazole and rabeprazole irrespective of genotype on day 7 of administration. In conclusion, on day 1 the time to onset of the antisecretory action of 20 mg/day omeprazole was more rapid than that of 10 mg/day rabeprazole in Japanese individuals who have a higher incidence of the CYP2C19 poor metabolizer genotype, however by day 7 no difference in antisecretory effect was found, regardless of genotype.
这项双向交叉研究调查了质子泵抑制剂奥美拉唑和雷贝拉唑对不同细胞色素P450 2C19(CYP2C19)基因型的日本受试者胃酸分泌影响的可能差异。总共23名幽门螺杆菌阴性的健康志愿者接受了每日20毫克的奥美拉唑和每日10毫克的雷贝拉唑治疗。每种药物治疗持续7天,给药顺序随机分配,药物治疗期之间间隔至少1周以进行洗脱。在第1天和第7天测量胃内pH值。首次给药后7和8小时的总体胃内pH值中位数,奥美拉唑组显著更高。纯合子广泛代谢者的胃内pH值无显著差异,而在杂合子广泛代谢者和慢代谢者的合并数据中,首次给药后6、7和8小时,奥美拉唑组的胃内pH值显著更高。给药第7天,无论基因型如何,奥美拉唑和雷贝拉唑之间的胃内pH值均无显著差异。总之,在第1天,对于CYP2C19慢代谢者基因型发生率较高的日本个体,每日20毫克奥美拉唑的抗分泌作用起效时间比每日10毫克雷贝拉唑更快,然而到第7天,无论基因型如何,均未发现抗分泌效果存在差异。